Claudia M Palena

List of Publications by Year
in descending order

102 papers	5,845 citations	94433 37 h-index	88630 70 g-index
102 all docs	102 docs citations	102 times ranked	7400 citing authors

#	Article	IF	Citations
1	Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-Î² signaling enables PD-L1â€“mediated tumor eradication. Journal of Clinical Investigation, 2022, 132, .	8.2	50
2	Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. , 2021, 219, 107692.		128
3	Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. Cancers, 2021, 13, 968.	3.7	9
4	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2021, 9, e002374.		25
5	A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.. Journal of Clinical Oncology, 2021, 39, 2617-2617.	1.6	0
6	Systemic Immune Response in Murine Bilateral Pheochromocytoma Model During Immunotherapy Based on a Combination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibodies (MBTA Therapy). Journal of the Endocrine Society, 2021, 5, A1032-A1033.	0.2	0
7	Behind the IL-8 ball in prostate cancer. Nature Cancer, 2021, 2, 775-776.	13.2	3
8	Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy. Cancers, 2021, 13, 3942.	3.7	7
9	T Cellâ€“Mediated Antitumor Immunity Cooperatively Induced By TGFÎ²R1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 1926-1940.	4.1	9
10	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. , 2021, 9, e003238.		19
11	A rare insight into the immunosuppressive landscape of prostate cancer bone metastases. Cancer Cell, 2021, 39, 1450-1452.	16.8	2
12	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. Oncologist, 2020, 25, 479-e899.	3.7	39
13	The Use of a Humanized NSG-Î²2mâˆ'/âˆ' Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa. Frontiers in Oncology, 2020, 10, 549.	2.8	19
14	Tumor Plasticity and Resistance to Immunotherapy. Trends in Cancer, 2020, 6, 432-441.	7.4	88
15	Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. Oncologist, 2020, 25, 560.	3.7	17
16	Dual targeting of TGF-Î² and PD-L1 via a bifunctional anti-PD-L1/TGF-Î²RII agent: status of preclinical and clinical advances. , 2020, 8, e000433.		166
17	Simultaneous inhibition of CXCR1/2, TGF-Î², and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. , 2020, 8, e000326.		54
18	Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. Frontiers in Oncology, 2020, 10, 581801.	2.8	11

#	Article	IF	Citations
19	Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy. Cancer Immunology Research, 2019, 7, 1359-1370.	3.4	22
20	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. , 2019, 7, 240.		162
21	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. Clinical Cancer Research, 2019, 25, 4933-4944.	7.0	45
22	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight, 2019, 4, .	5.0	168
23	Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 2640-2640.	1.6	0
24	Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack. Frontiers in Oncology, 2018, 8, 143.	2.8	7
25	Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.. Journal of Clinical Oncology, 2018, 36, 3091-3091.	1.6	16
26	Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition. Cells Tissues Organs, 2017, 203, 128-138.	2.3	20
27	Brachyury. , 2017, , 95-107.		0
28	Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. Vaccine, 2017, 35, 2605-2611.	3.8	17
29	Pharmacological and immunological targeting of tumor mesenchymalization. , 2017, 170, 212-225.		14
30	Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer. Cell Reports, 2017, 21, 495-507.	6.4	59
31	Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. Seminars in Cancer Biology, 2017, 47, 177-184.	9.6	128
32	A novel bifunctional anti-PD-L1/TGF-Î² Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. OncoImmunology, 2017, 6, e1349589.	4.6	137
33	CBIO-01. TRANSCRIPTIONAL MODULATION OF BRACHYURY IN CHORDOMA. Neuro-Oncology, 2017, 19, vi32-vi33.	1.2	1
34	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. Clinical Cancer Research, 2017, 23, 6833-6845.	7.0	51
35	Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight, 2017, 2, .	5.0	112
36	The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. Vaccines, 2016, 4, 22.	4.4	286

#	Article	IF	Citations
37	MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition. OncoImmunology, 2016, 5, e1117738.	4.6	53
38	Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. Endocrine-Related Cancer, 2016, 23, 783-796.	3.1	31
39	Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies. Cell Death and Disease, 2016, 7, e2380-e2380.	6.3	38
40	Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer. Clinical Cancer Research, 2016, 22, 6204-6216.	7.0	49
41	Abstract 4032: Modulation of tumor PD-L1 expression by epithelial-mesenchymal phenotypic plasticity. , 2016, , .		0
42	Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas. American Journal of Surgical Pathology, 2015, 39, 1305-1312.	3.7	122
43	Immune Targeting of Tumor Epithelialâ€"Mesenchymal Transition via Brachyury-Based Vaccines. Advances in Cancer Research, 2015, 128, 69-93.	5.0	12
44	Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody. Oncotarget, 2015, 6, 4853-4862.	1.8	24
45	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Oncotarget, 2015, 6, 31344-31359.	1.8	32
46	An immunotherapeutic intervention against tumor progression. OncoImmunology, 2014, 3, e27220.	4.6	27
47	Therapeutic Cancer Vaccines. Advances in Cancer Research, 2014, 121, 67-124.	5.0	68
48	The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors. , 2014, , 315-334.		0
49	Overexpression of the EMT Driver Brachyury in Breast Carcinomas: Association With Poor Prognosis. Journal of the National Cancer Institute, 2014, 106, .	6.3	65
50	Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer Immunology, Immunotherapy, 2014, 63, 1307-1317.	4.2	23
51	Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process. Cancer Research, 2014, 74, 1945-1957.	0.9	31
52	WEE1 Inhibition Alleviates Resistance to Immune Attack of Tumor Cells Undergoing Epithelialâ€"Mesenchymal Transition. Cancer Research, 2014, 74, 2510-2519.	0.9	71
53	The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance. , 2014, 2, .		0
54	NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma.. Journal of Clinical Oncology, 2014, 32, 3081-3081.	1.6	6

#	Article	IF	Citations
55	A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma.. Journal of Clinical Oncology, 2014, 32, e14026-e14026.	1.6	2
56	Brachyury. , 2014, , 1-13.		0
57	Chemotherapyâ€induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. International Journal of Cancer, 2013, 133, 624-636.	5.1	225
58	Recombinant TRICOM-based Therapeutic Cancer Vaccines. , 2013, , 309-331.		1
59	The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death and Disease, 2013, 4, e682-e682.	6.3	70
60	An Autocrine Loop between TGF-Î²1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype. Molecular Cancer Therapeutics, 2013, 12, 1805-1815.	4.1	57
61	Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget, 2013, 4, 1777-1790.	1.8	63
62	Abstract 278: High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack.. , 2013, , .		0
63	Abstract 1260: Generation of human T cells directed against an agonist epitope of a transcription factor involved in epithelial to mesenchymal transition (EMT).. , 2013, , .		0
64	Abstract 1676: Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.. , 2013, , .		0
65	Abstract 1489: The T-box transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to chemotherapy and radiation.. , 2013, , .		1
66	Influence of IL-8 on the epithelialâ€"mesenchymal transition and the tumor microenvironment. Future Oncology, 2012, 8, 713-722.	2.4	138
67	Brachyury, a Driver of the Epithelialâ€"Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer. Clinical Cancer Research, 2012, 18, 3868-3879.	7.0	112
68	Cancer Vaccines Targeting the Epithelial-Mesenchymal Transition: Tissue Distribution of Brachyury and Other Drivers of the Mesenchymal-Like Phenotype of Carcinomas. Seminars in Oncology, 2012, 39, 358-366.	2.2	48
69	IL-8 Signaling Plays a Critical Role in the Epithelialâ€"Mesenchymal Transition of Human Carcinoma Cells. Cancer Research, 2011, 71, 5296-5306.	0.9	346
70	Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells. Experimental Biology and Medicine, 2011, 236, 537-545.	2.4	31
71	Abstract SY24-02: Development of recombinant vaccines for the prevention and therapy of human carcinomas. , 2011, , .		0
72	Abstract A64: Brachyury-mediated epithelial-mesenchymal transition of human carcinoma cells is associated with an increased resistance to immune-mediated attack. , 2011, , .		0

#	Article	IF	Citations
73	Abstract C53: Overexpression of Brachyury in human carcinoma cells drives the acquisition of resistance to anticancer therapeutics. , 2011, , .		0
74	New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunology, Immunotherapy, 2010, 59, 63-71.	4.2	28
75	Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells. Leukemia Research, 2010, 34, 1351-1357.	0.8	14
76	Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-12.	3.0	41
77	The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. Journal of Clinical Investigation, 2010, 120, 533-544.	8.2	238
78	Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. Cancer Immunology, Immunotherapy, 2009, 58, 955-965.	4.2	17
79	176 Vector-based Vaccines for Cancer Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, .	2.1	0
80	Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma. Clinical Cancer Research, 2008, 14, 3060-3069.	7.0	208
81	The Human T-Box Mesodermal Transcription Factor Brachyury Is a Candidate Target for T-Cellâ€"Mediated Cancer Immunotherapy. Clinical Cancer Research, 2007, 13, 2471-2478.	7.0	150
82	IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood, 2007, 110, 3192-3201.	1.4	177
83	Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). International Journal of Cancer, 2007, 121, 595-605.	5.1	19
84	Cancer Vaccines: Preclinical Studies and Novel Strategies. Advances in Cancer Research, 2006, 95, 115-145.	5.0	64
85	Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis. Clinical Cancer Research, 2006, 12, 1897-1905.	7.0	85
86	Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood, 2005, 106, 3515-3523.	1.4	32
87	Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules. Clinical Cancer Research, 2005, 11, 1597-1607.	7.0	44
88	Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin. Clinical Cancer Research, 2005, 11, 6342-6351.	7.0	56
89	Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes. Cancer Research, 2004, 64, 7985-7994.	0.9	489
90	A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1. Clinical Cancer Research, 2004, 10, 2139-2149.	7.0	60

#	Article	IF	Citations
91	Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood, 2004, 104, 192-199.	1.4	31
92	Modification of B-CLL Cells Via Infection with a Replication-Defective MVA Virus Encoding Three Costimulatory Molecules: A Potential Approach to Tumor Cell Immunotherapy of B-CLL.. Blood, 2004, 104, 2516-2516.	1.4	0
93	A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. Journal of Immunological Methods, 2003, 279, 183-192.	1.4	5
94	Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens. Cytokine, 2003, 24, 128-142.	3.2	14
95	Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptide. Clinical Cancer Research, 2003, 9, 1616-27.	7.0	9
96	Positively charged residues at the N-terminal arm of the homeodomain are required for efficient DNA binding by homeodomain-leucine zipper proteins11Edited by M. Yaniv. Journal of Molecular Biology, 2001, 308, 39-47.	4.2	37
97	A monomerâ€"dimer equilibrium modulates the interaction of the sunflower homeodomain leucine-zipper protein Hahb-4 with DNA. Biochemical Journal, 1999, 341, 81-87.	3.7	68
98	A monomerâ€'dimer equilibrium modulates the interaction of the sunflower homeodomain leucine-zipper protein Hahb-4 with DNA. Biochemical Journal, 1999, 341, 81.	3.7	51
99	Homeoboxes in plant development. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1442, 1-19.	2.4	192
100	Expression of Sunflower Homeodomain Containing Proteins inEscherichia coli:Purification and Functional Studies. Protein Expression and Purification, 1998, 13, 97-103.	1.3	22
101	A novel type of dimerization motif, related to leucine zippers, is present in plant homeodomain proteins. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1997, 1352, 203-212.	2.4	9
102	IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget, 0, 7, 42031-42044.	1.8	48